growth of 1% in constant currency, Zimmer trailed rivals Stryker and Johnson & Johnson's DePuy business. In recent quarters ..... Zimmer's geographical contributions were a mirror image of Stryker 's—with much stronger international growth compensating
targets. Observers believe there will be more acquisitions consummated before Congress puts limits on the maneuvers. Stryker (NYSE: SYK ) has been mentioned as a potential suitor for Smith& Nephew. Pfizer (NYSE: PFE ) may make another run at AstraZeneca
Stryker 's recalled metal-on-metal ..... care costs could increase Stryker 's vulnerability to larger ..... employees is the linchpin for Stryker 's moat in orthopedics. Stryker ..... spine growth. We estimate Stryker should be able make incremental
Stryker 's strong second-quarter results leave the firm on track to ..... incorporating the impact of acquisition activity and a reduction in Stryker 's effective tax rate. Stryker continues to pursue its strategy to gain scale in its markets
Stryker Corporation (NYSE: SYK ) Q2 2014 Results Earnings Conference Call July 17, 2014, 2 ..... Richard Newitter - Leerink Partners Presentation Operator Welcome to Stryker 's second quarter 2014 earnings conference call. My name is Adrienne
July 17 (Reuters) - U.S. orthopedics company Stryker Corp on Thursday reported slightly higher second-quarter profit that was in line with Wall Street expectations and said it was always in the market for deals.
July 17 (Reuters) - U.S. orthopedics company Stryker Corp on Thursday reported slightly higher second-quarter profit that was in line with Wall Street expectations on increased sales of reconstructive and surgical products.
Stryker ( SYK -0.7% ) Q2 results: Net Sales: $2,363M (+6.8%); COGS: $808M (+10.7%); R&D Expense: $158M (+19
Stryker Corporation (NYSE: SYK ): Q2 EPS of $1.08 in-line. Revenue of $2.36B (+6.8% Y/Y) beats by $10M . Press Release Post your comment!
into a definitive agreement with Stryker ( SYK -0.1% ) to acquire its Bone ..... 450 issued and pending patents, Stryker 's BMP-7-related clinical and ..... associated biologic materials. Stryker will have the right of first negotiation